A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure

NCT02157506 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Heart Failure
Decompensated Heart Failure
Acute Heart Failure

Interventions

DRUG: CXL-1427
DRUG: Placebo

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]